ongoing

Heart failure (HF) is a rapidly increasing disease worldwide but there is no global HF study that documents demographics, socioeconomic and clinical factors, diagnostic and management patterns, etiology, biomarkers, co-morbidities, treatments, quality of life, barriers to care and outcomes in all parts of the world. Such knowledge is essential in the prevention and treatment of this global disease.

The primary event outcome of the study will be mortality, by cause. Secondary event outcomes will include non-fatal major events (both resulting in and not resulting in hospitalization).

The G-CHF study will obtain baseline data on participants, from North America, South America, Europe, Africa, Asia and the Middle East, on demographic and socioeconomic data, clinical and laboratory variables, echocardiography, HF etiology, medication use, management patterns, quality of life, barriers to care and health systems. Six-month, 12-month, 18-month and 24-month follow-up data will be obtained to determine changes in management, and patient outcomes.

A sub-study of approximately 4000-5000 patients to measure frailty, cognitive and lung function, mental health, medication adherence, patient-reported barriers to care, dietary assessment, and collection of blood samples for central analysis will additionally be performed.

Study Type

Observational - registry

Study Design

Prospective global registry

NO. of Countries

39

NO. of Sites

300

NO. of Participants

22500

Study Period

2016-2023

Sponsor

PHRI

Bayer

Back To Top